ClinicalTrials.gg
CompletedNCT01856764Updated Feb 1, 2017Results posted

Topical Roflumilast in Adults With Atopic Dermatitis

A Phase 2 interventional study of 0.5% Roflumilast Cream and Vehicle Cream in Atopic Dermatitis, sponsored by AstraZeneca. Completed at 3 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing roflumilast in Dermatitis, Atopic — 4 open to participants now, 4 under way, 1 of them phase 3. Roflumilast · Dermatitis, Atopic.

Enrollment
10th of 13
40 · median 136
Started
2013
the only one that year
Phase 2
4 of 13
1 open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
AstraZeneca

Among the 13 studies testing roflumilast in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2013, is one of 4 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 13 studies testing roflumilast in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing roflumilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of topical roflumilast on the reduction of atopic dermatitis lesions in adults with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female between 18 to 65 years of age, inclusive, with atopic dermatitis (AD) meeting Hanifin and Rajka's criteria.
  2. Has lesional skin areas of moderate severity characterized by modified local SCORing Atopic Dermatitis (SCORAD) of at least 4, with an erythema score ≥2, and confirmed by a qualified investigator.
  3. Has an index/target lesion of moderate severity approximately 20 cm\^2, suitable for topical treatment.
  4. Is willing to wash out from AD current active therapy prior to entry in the study.
  5. Is willing and able to apply the study medication as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
  6. If a male who is nonsterilized and sexually active with a female partner of , agrees to use adequate from signing of throughout the duration of the study and for 12 weeks after last dose.
  7. If a female of childbearing potential who is sexually active with a nonsterilized male partner, agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last dose.
  8. Is capable of understanding and complying with protocol requirements in the opinion of the investigator.
  9. Signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound within 30 days, or within 5 half-lives of the compound (whichever is longer) prior to the Screening visit.
  2. Has a history of AD unresponsive or poorly responsive to topical treatments.
  3. Has a history of to phosphodiesterase (PDE)-4 inhibitors or to drugs of similar chemical classes or any inactive ingredients of the trial medication.
  4. Has abnormal hematological parameters of , hematocrit or erythrocytes at Screening, in the judgment of the investigator.
  5. Has a history or current clinically relevant allergy or idiosyncrasy to drugs or food.
  6. Had extensive exposure to ultraviolet (UV) light in the 4 weeks prior to first application of study medication, including tanning and sun beds or is intending to have such exposure during the study treatment that may interfere with the study assessments as judged by the investigator.
  7. Has evidence of oozing of target lesion.
  8. Has a current skin complication such as erythroderma or overt bacterial or viral infection for which treatment with anti-infectives are indicated.
  9. Had systemic treatment with or retinoids for studied condition within 3 months prior to the first application of study medication.
  10. Had topical or transdermal treatments, such as but not limited to retinoids, nicotine or hormone replacement therapies, on or near the intended site of application within 4 weeks prior to first application of study medication.
  11. Had treatment with systemic/locally acting medications/procedures that might counter or influence the study aim within 4 weeks prior to first application of study medication and during the study (e.g., anti-histamines).
  12. Has used emollients/moisturizers on areas to be treated within 24 hours prior to the first application of study medication.
  13. Has used biologics at any time for treatment of AD.
  14. Is currently enrolled in an investigational drug or device study.
  15. Has any clinically significant illness that may influence the outcome of the trial from 4 weeks before Day 1 through trial completion.
  16. Has (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 × (ULN), or other clinically significant abnormal laboratory test that, in the opinion of the Investigator, would compromise the participant's ability to safely complete the trial.
  17. Has a significant medical condition and/or conditions that, in the opinion of the Investigator, would interfere with the treatment, safety or compliance with the protocol.
  18. Has a history of infection with , , or .
  19. Has a history of alcoholism or illicit drug abuse within 5 years prior to the Screening Visit or is currently consuming >14 alcoholic drinks per week.
  20. If female, is pregnant, nursing or planning a pregnancy during the study period.
  21. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study medication. This criterion does not apply to those participants with successfully resected basal cell or stage I squamous cell carcinoma of the skin.
  22. Has a chronic or clinically relevant acute infection.
  23. Has a history of depression associated with suicidal ideation and behavior.
  24. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.
  25. Is an immediate family member, a study site employee, in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or at risk for consenting under duress.
  26. Was institutionalized because of a legal or regulatory order.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    0.5% Roflumilast Cream

    Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.

    Drug: 0.5% Roflumilast Cream

  • Placebo comparator
    Vehicle Cream

    Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.

    Drug: Vehicle Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)

    Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.

    Time frame: Baseline and Day 15

Secondary outcomes

  1. Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values

    Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.

    Time frame: Baseline and Day 15

  2. Change From Baseline to Day 15 in Participants' Assessment of Pruritus

    Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.

    Time frame: Baseline and Day 15

07

Results

Posted Jul 7, 2015

Participant flow

Participants took part in the study at 3 centers in Germany from 10 June 2013 to 18 March 2014.

Participant flow — Overall Study
Milestone0.5% Roflumilast CreamVehicle Cream
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryChange From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)

Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)
Scores on a scale0.5% Roflumilast CreamVehicle Cream
Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)-2.30 ± 0.354-1.75 ± 0.347
Statistical analysis
  • 0.5% Roflumilast Cream vs Vehicle Cream · Mixed Models Analysis · p = 0.276 (Mixed Model Repeated Measures (MMRM) Model: SCORAD change from baseline = treatment + visit + treatment by visit interaction + baseline SCORAD score) · Ls mean difference: -0.55 · 95% CI -1.5542 to 0.4574
SecondaryChange From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values

Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · g/m^2/hr
Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values
g/m^2/hr0.5% Roflumilast CreamVehicle Cream
Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values-18.60 ± 2.467-12.69 ± 2.417
Statistical analysis
  • 0.5% Roflumilast Cream vs Vehicle Cream · Mixed Models Analysis · p = 0.095 (MMRM model: TEWL change from baseline = treatment + visit + treatment by visit interaction + baseline TEWL score) · Ls mean difference: -5.91 · 95% CI -12.9134 to 1.0835
SecondaryChange From Baseline to Day 15 in Participants' Assessment of Pruritus

Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.

Time frame:
Baseline and Day 15
Reported as:
Least squares mean · Scores on a scale
Change From Baseline to Day 15 in Participants' Assessment of Pruritus
Scores on a scale0.5% Roflumilast CreamVehicle Cream
Change From Baseline to Day 15 in Participants' Assessment of Pruritus-3.05 ± 0.426-1.50 ± 0.417
Statistical analysis
  • 0.5% Roflumilast Cream vs Vehicle Cream · Mixed Models Analysis · p = 0.013 (MMRM model: Assessment of Pruritus change from baseline = treatment + visit + treatment by visit interaction + baseline Assessment of Pruritus score) · Ls mean difference: -1.56 · 95% CI -2.7656 to -0.3492

Adverse events

Collected over From the time informed consent is signed through 7 days after the last dose of study drug (up to Day 22). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5% Roflumilast Cream—0/20 (0%)5/20 (25%)
Vehicle Cream—0/20 (0%)3/20 (15%)
Most frequent other events
Most frequent other events
Event0.5% Roflumilast CreamVehicle Cream
NasopharyngitisInfections and infestations3/200/20
Application Site PainGeneral disorders1/201/20
Gamma-glutamyltransferase increasedInvestigations1/200/20
Alanine aminotransferase increasedInvestigations1/200/20
ArthralgiaMusculoskeletal and connective tissue disorders1/200/20
Red blood cells urineInvestigations0/201/20
Blood creatine phosphokinase increasedInvestigations0/201/20

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(Years)0.5% Roflumilast CreamVehicle CreamTotal
Mean32.7 ± 11.5036.5 ± 9.6534.6 ± 10.66
Gender
Gender(Participants)0.5% Roflumilast CreamVehicle CreamTotal
Female91120
Male11920
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.5% Roflumilast CreamVehicle CreamTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White202040
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)0.5% Roflumilast CreamVehicle CreamTotal
Germany202040
Height
Height(centimeters)0.5% Roflumilast CreamVehicle CreamTotal
Mean177.3 ± 9.27174.9 ± 10.13176.1 ± 9.66
Weight
Weight(kilograms)0.5% Roflumilast CreamVehicle CreamTotal
Mean81.72 ± 21.75778.31 ± 12.96580.02 ± 17.762
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)0.5% Roflumilast CreamVehicle CreamTotal
Mean25.65 ± 5.00725.59 ± 3.47725.62 ± 4.255
Smoking Classificaiton
Smoking Classificaiton(participants)0.5% Roflumilast CreamVehicle CreamTotal
Never smoked5813
Current smoker10919
Ex-Smoker538

4 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Berlin, Germany
  • Gera, Germany
  • Hamburg, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2013
First posted
May 17, 2013
Start
Jun 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Jul 7, 2015
Last update
Feb 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01856764
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 17, 2013
Start date
Jun 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Jul 7, 2015
Last update
Feb 1, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion